<DOC>
	<DOCNO>NCT02390492</DOCNO>
	<brief_summary>This 2-period , open-label , nonrandomized study conduct determine absolute bioavailability well absorption , metabolism , excretion ipatasertib metabolite ( ) . Healthy male participant receive single 200-mg oral dose ipatasertib follow 1 hour later 80-mcg/800-nCi intravenous dose [ 14C ] -ipatasertib . After 4-day observation period 10-day washout , participant receive single 200-mg/100-mcCi oral dose [ 14C ] -ipatasertib subsequent data collection additional 7 14 day discharge criterion meet .</brief_summary>
	<brief_title>A Phase I Bioavailability Pharmacokinetic Study 14C-Ipatasertib Single Oral Intravenous Doses Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer 18 55 year age , inclusive Body mass index ( BMI ) 18 32 kg/m2 , inclusive Females Clinically significant finding medical history screening evaluation Recent participation investigational drug study biologic agent study , receipt previous radiolabeled investigational drug within 6 month prior checkin Significant radiation exposure within 12 month prior checkin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>